Shakeela Bahadur, MD

Articles by Shakeela Bahadur, MD

Dr Bahadur on the Shift in Frontline CDK4/6 Inhibitor Selection in HR+/ HER2– Breast Cancer Breast Cancer

July 6th 2023

Shakeela Bahadur, MD, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Latest Updated Articles

Trending on OncLive

CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026

Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS

FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer